Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

Abstract Background This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheum...

Full description

Bibliographic Details
Main Authors: Michael Schiff, Tsutomu Takeuchi, Roy Fleischmann, Carol L. Gaich, Amy M. DeLozier, Douglas Schlichting, Wen-Ling Kuo, Ji-Eon Won, Tara Carmack, Terence Rooney, Patrick Durez, Saeed Shaikh, Rodolfo Pardo Hidalgo, Ronald van Vollenhoven, Cristiano A. F. Zerbini
Format: Article
Language:English
Published: BMC 2017-09-01
Series:Arthritis Research & Therapy
Subjects:
Baricitinib
PRO
JAK inhibitor
RA
Rheumatoid
tsDMARD
Online Access:http://link.springer.com/article/10.1186/s13075-017-1410-1

Internet

http://link.springer.com/article/10.1186/s13075-017-1410-1

Similar Items